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Cognitive Enhancement 
Abstract 
Cognitive enhancement refers to the improvement of cognitive ability in normal healthy individuals. In this 
article, we focus on the use of pharmaceutical agents and brain stimulation for cognitive enhancement, 
reviewing the most common methods of pharmacologic and electronic cognitive enhancement, and the 
mechanisms by which they are believed to work, the effectiveness of these methods and their prevalence. 
We note the many gaps in our knowledge of these matters, including open questions about the size, 
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ABSTRACT	  	  Cognitive	  enhancement	  refers	  to	  the	  improvement	  of	  cognitive	  ability	  in	  normal	  healthy	  individuals.	  	  In	  this	  article	  we	  focus	  on	  the	  use	  of	  pharmaceutical	  agents	  and	  brain	  stimulation	  for	  cognitive	  enhancement,	  reviewing	  the	  most	  common	  methods	  of	  pharmacologic	  and	  electronic	  cognitive	  enhancement,	  and	  the	  mechanisms	  by	  which	  they	  are	  believed	  to	  work,	  the	  effectiveness	  of	  these	  methods	  and	  their	  prevalence.	  	  We	  note	  the	  many	  gaps	  in	  our	  knowledge	  of	  these	  matters,	  including	  open	  questions	  about	  the	  size,	  reliability	  and	  nature	  of	  the	  enhancing	  effects,	  and	  we	  conclude	  with	  recommendations	  for	  further	  research.	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Cognitive	  enhancement	  refers	  to	  the	  improvement	  of	  cognitive	  ability	  in	  normal	  healthy	  individuals*.	  	  There	  are	  many	  ways	  to	  boost	  levels	  of	  cognitive	  ability,	  including	  engaging	  in	  physical	  exercise	  (Smith	  et	  al.,	  2010)	  and	  meditating	  (Chiesa,	  Calati	  &	  Serretti,	  2011).	  	  However,	  the	  term	  “cognitive	  enhancement”	  is	  usually	  used	  in	  connection	  with	  interventions	  applied	  more	  directly	  to	  the	  brain:	  pharmaceutical	  agents	  and	  brain	  stimulation.	  	  In	  this	  article	  we	  will	  focus	  on	  these	  neurotechnological	  methods	  for	  cognitive	  enhancement,	  which	  have	  attracted	  great	  public	  interest	  in	  recent	  years	  and	  a	  growing	  number	  of	  users.	  	  We	  begin	  the	  review	  by	  surveying	  the	  most	  common	  methods	  of	  pharmacologic	  and	  electrophysiologic	  cognitive	  enhancement	  and	  the	  mechanisms	  by	  which	  they	  may	  work.	  	  We	  then	  review	  what	  is	  known	  about	  the	  effectiveness	  of	  these	  forms	  of	  enhancement	  and	  their	  prevalence,	  noting	  the	  many	  gaps	  in	  our	  knowledge	  of	  these	  matters.	  	  We	  conclude	  with	  recommendations	  for	  further	  research	  and	  policy.	  	  
THREE	  CLASSES	  OF	  DRUGS	  WITH	  COGNITIVE	  ENHANCEMENT	  POTENTIAL	  	  Potential	  pharmacologic	  cognitive	  enhancers	  include	  a	  variety	  of	  drugs	  developed	  to	  treat	  cognitive	  dysfunction.	  	  That	  is,	  these	  drugs	  were	  developed	  with	  the	  goal	  of	  moving	  cognitively	  impaired	  individuals	  upward	  on	  the	  ability	  scale	  toward	  a	  normal	  level.	  	  These	  same	  drugs	  have	  been	  used	  as	  cognitive	  enhancers	  by	  normal	  individuals	  in	  an	  attempt	  to	  achieve	  “better	  than	  normal”	  cognitive	  ability.	  	  Although	  many	  different	  substances	  have	  been	  used	  for	  this	  purpose	  (Dean,	  Morgenthaler	  &	  Fowkes,	  1993),	  three	  well-­‐known	  classes	  of	  drug	  in	  current	  clinical	  use	  will	  be	  discussed	  here:	  the	  traditional	  stimulants,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  *	  The	  term	  is	  sometimes	  also	  used	  in	  connection	  with	  treatments	  for	  cognitive	  disorders	  such	  as	  dementia.	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primarily	  used	  to	  treat	  Attention	  Deficit	  Hyperactivity	  Disorder,	  the	  acetylcholinesterase	  inhibitors,	  used	  to	  treat	  Alzheimer’s	  disease,	  and	  modafinil,	  a	  novel	  stimulant	  primarily	  used	  to	  treat	  narcolepsy.	  	  
Stimulants.	  	  Stimulants	  include	  methylphenidate,	  best	  known	  as	  Ritalin	  or	  Concerta,	  and	  amphetamine,	  most	  widely	  prescribed	  as	  mixed	  AMP	  salts	  consisting	  primarily	  of	  dextroamphetamine	  (d-­‐AMP),	  known	  by	  the	  trade	  name	  Adderall.	  These	  medications	  have	  become	  familiar	  to	  the	  general	  public	  because	  of	  the	  growing	  rates	  of	  diagnosis	  of	  ADHD	  children	  and	  adults	  (CDC,	  2010;	  Sankaranarayanan,	  Puumala,	  &	  Kratochvil,	  2006)	  and	  the	  recognition	  that	  these	  medications	  are	  effective	  for	  treating	  ADHD	  (MTA	  Cooperative	  Group,	  1999;	  Swanson	  et	  al.,	  2008).	  	  Methylphenidate	  and	  amphetamine	  affect	  the	  catecholamines	  dopamine	  and	  norepinephrine,	  which	  are	  key	  neurotransmitters	  in	  the	  cortical	  and	  subcortical	  systems	  that	  enable	  us	  to	  focus	  and	  flexibly	  deploy	  attention	  (Robbins	  &	  Arnsten,	  2009).	  	  	  The	  therapeutic	  effect	  of	  these	  drugs	  for	  ADHD	  is	  consistent	  with	  the	  finding	  of	  abnormalities	  in	  the	  catecholamine	  system	  in	  patients	  with	  ADHD	  (e.g.,	  Volkow	  et	  al.,	  2007).	  Both	  drugs	  exert	  their	  effects	  on	  cognition	  primarily	  by	  increasing	  levels	  of	  catecholamines	  in	  prefrontal	  cortex	  and	  the	  cortical	  and	  subcortical	  regions	  projecting	  to	  it,	  and	  this	  mechanism	  is	  responsible	  for	  improving	  attention	  in	  ADHD	  (Pliszka,	  2005;	  Wilens,	  2006).	  	  Cognitive	  enhancement	  use	  of	  stimulants	  is	  aimed	  at	  improving	  the	  same	  attentional	  systems	  in	  normal,	  healthy	  people.	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Acetylcholinesterase	  inhibitors.	  Another	  class	  of	  drugs	  with	  enhancement	  potential	  is	  the	  aeytylcholinesterase	  inhibitors,	  widely	  used	  for	  the	  treatment	  of	  mild	  to	  moderate	  Alzheimer’s	  disease.	  	  These	  drugs,	  including	  donepizil	  (Aricept),	  rivastigmine	  (Excelon)	  and	  galantamine	  (Razadyne),	  increase	  levels	  of	  the	  neurotransmitter	  acetylcholine	  in	  the	  brain	  by	  decreasing	  the	  activity	  of	  the	  enzyme	  that	  normally	  breaks	  down	  acetylcholine.	  	  Degeneration	  of	  cholinergic	  neurons	  is	  a	  central	  factor	  in	  the	  cognitive	  decline	  of	  Alzheimer’s	  disease.	  	  More	  generally,	  acetylcholine	  plays	  a	  broad	  role	  in	  normal	  cognition	  (Furey,	  2011)	  and	  might	  therefore	  be	  target	  for	  pharmacologic	  cognitive	  enhancement.	  	  
Modafinil.	  	  Modafinil,	  marketed	  as	  Provigil,	  was	  originally	  developed	  for	  the	  treatment	  of	  daytime	  sleepiness	  in	  patients	  suffering	  from	  narcolepsy,	  and	  is	  now	  approved	  by	  the	  US	  FDA	  for	  sleepiness	  associated	  with	  sleep	  apnea	  and	  shift-­‐work	  sleep	  disorder.	  	  In	  addition	  to	  improving	  subjective	  feelings	  of	  energy	  and	  alertness	  in	  sleep-­‐deprived	  individuals,	  it	  improves	  their	  cognitive	  performance	  on	  objective	  tests	  (Wesensten,	  2006).	  	  Some	  studies	  have	  found	  cognitive	  enhancing	  effects	  in	  normal	  subjects	  who	  are	  not	  sleep	  deprived	  (Turner	  et	  al.,	  2003).	  	  In	  addition	  to	  its	  use	  for	  the	  three	  FDA-­‐approved	  indications	  it	  has	  been	  prescribed	  off-­‐label	  for	  a	  much	  wider	  range	  of	  indications,	  including	  depression,	  attention	  deficit	  hyperactivity	  disorder	  and	  jet	  lag	  (Minzenberg	  &	  Carter,	  2008).	  	  	  Its	  mechanism	  of	  action	  is	  different	  from	  the	  traditional	  stimulants,	  which	  have	  also	  been	  used	  to	  counteract	  the	  effects	  of	  sleep	  deprivation,	  but	  much	  remains	  to	  be	  understood	  about	  how	  it	  works.	  	  In	  addition	  to	  affecting	  dopamine	  and	  norepinephrine,	  it	  is	  also	  believed	  to	  affect	  gamma-­‐aminobutyric	  acid,	  glutamate,	  histamine	  and	  orexin/hypocretin	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(Minzenberg	  &	  Carter,	  2008).	  	  Enhancement	  use	  of	  modafinil	  involves	  staving	  off	  the	  cognitive	  decline	  associated	  with	  sleep	  deprivation	  and	  additionally	  the	  possibility	  of	  subtle	  cognitive	  improvements	  in	  well-­‐rested	  individuals.	  	  
BRAIN	  STIMULATION	  FOR	  COGNITIVE	  ENHANCEMENT	  	  The	  literature	  on	  noninvasive	  brain	  stimulation	  has	  grown	  rapidly	  since	  the	  turn	  of	  the	  century.	  	  Transcranial	  magnetic	  stimulation	  (TMS)	  and	  transcranial	  direct	  current	  stimulation	  (tDCS)	  are	  the	  two	  most	  commonly	  employed	  methods	  available	  for	  use	  in	  humans.	  	  Each	  was	  explored	  by	  scientists	  initially	  as	  a	  research	  tool	  for	  studying	  brain	  function,	  although	  more	  recently	  the	  therapeutic	  and	  enhancement	  potential	  of	  these	  methods	  has	  also	  been	  explored.	  	  TMS	  utilizes	  electromagnetic	  induction	  and	  involves	  the	  generation	  of	  a	  rapid	  time-­‐varying	  magnetic	  field	  in	  a	  coil	  of	  wire.	  When	  this	  coil	  is	  held	  to	  the	  head	  of	  a	  subject,	  the	  magnetic	  field	  penetrates	  the	  scalp	  and	  skull,	  inducing	  a	  small	  current	  parallel	  to	  the	  plane	  of	  the	  coil	  in	  the	  brain	  that	  is	  sufficient	  to	  depolarize	  neuronal	  membranes	  and	  generate	  action	  potentials.	  Different	  TMS	  paradigms	  employ	  a	  variety	  of	  pulse	  frequencies,	  intensities,	  and	  stimulation	  locations	  to	  achieve	  specific	  diagnostic,	  therapeutic,	  and	  experimental	  effects.	  Repetitive	  TMS	  (rTMS)—which	  involves	  the	  application	  of	  a	  series	  of	  pulses	  that	  is	  presented	  at	  a	  predetermined	  frequency	  (typically	  >	  0.3	  Hz)—is	  especially	  germane	  to	  cognitive	  enhancement	  because	  it	  can	  produce	  effects	  that	  outlast	  the	  application	  of	  the	  stimulation.	  Evidence	  suggests	  that	  rTMS	  delivered	  at	  a	  low	  frequency	  (0.5-­‐2	  Hz)	  tends	  to	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focally	  decrease	  cortical	  excitability,	  whereas	  higher	  frequencies	  (faster	  than	  5	  Hz)	  tend	  to	  increase	  excitability	  (Maeda	  &	  Pascual-­‐Leone,	  2003).	  Because	  the	  spatial	  resolution	  of	  TMS	  is	  fairly	  high	  (approximately	  1	  cm2	  at	  the	  cortical	  surface),	  investigators	  typically	  identify	  stimulation	  targets	  carefully	  using	  scalp	  landmarks	  (e.g.	  the	  10-­‐20	  system	  used	  for	  EEG	  electrode	  placement),	  functional	  localizers	  (e.g.	  using	  evoked	  motor	  responses	  to	  locate	  the	  region	  of	  the	  motor	  cortex	  that	  represents	  specific	  hand	  muscles),	  or	  MRI-­‐guided	  neuronavigational	  systems	  (Sack	  et	  al.,	  2009).	  While	  studies	  in	  normal	  individuals	  have	  only	  demonstrated	  transient	  changes	  in	  cognition	  and	  behavior,	  limited	  evidence	  from	  TMS	  studies	  in	  patient	  populations	  suggests	  that	  repeated	  administration	  of	  TMS	  can	  lead	  to	  enduring	  changes	  in	  behavior,	  presumably	  due	  to	  persistent	  changes	  in	  patterns	  of	  neural	  activity	  (e.g.	  Naeser	  2005;	  Hamilton	  et	  al.,	  2010).	  TMS	  is	  currently	  being	  explored	  experimentally	  as	  a	  therapy	  for	  a	  variety	  of	  conditions	  including	  but	  not	  limited	  to	  motor	  and	  cognitive	  deficits	  after	  stroke,	  movement	  disorders,	  Alzheimer’s	  disease,	  epilepsy,	  migraines,	  and	  tinnitus	  (see	  Najib	  et	  al.,	  2011	  for	  a	  review).	  Since	  2008,	  TMS	  has	  been	  approved	  by	  the	  US	  FDA	  as	  a	  therapy	  for	  depression,	  and	  is	  currently	  being	  provided	  by	  mental	  health	  professionals	  across	  the	  country	  (http://www.neurostartms.com).	  	  
	  Transcranial	  direct	  current	  stimulation	  (tDCS)	  involves	  the	  application	  of	  small	  electrical	  currents	  to	  the	  scalp	  through	  two	  surface	  electrodes.	  Unlike	  TMS,	  which	  induces	  currents	  of	  sufficient	  magnitude	  to	  stimulate	  action	  potentials,	  the	  weak	  electrical	  currents	  employed	  in	  tDCS	  (typically	  1-­‐2	  mA)	  are	  thought	  to	  alter	  the	  resting	  membrane	  potentials	  of	  neurons	  incrementally,	  affecting	  the	  likelihood	  of	  firing	  of	  cortical	  neurons	  over	  time.	  The	  effects	  of	  tDCS	  depend	  on	  the	  polarity	  of	  the	  electrode	  applied	  to	  the	  scalp:	  cathodal	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stimulation	  is	  associated	  with	  decreased	  cortical	  excitability	  due	  to	  hyperpolarization	  of	  cortical	  neurons,	  while	  anodal	  stimulation	  is	  associated	  with	  increased	  cortical	  excitability	  due	  to	  subthreshold	  depolarization.	  These	  effects	  may	  last	  for	  minutes	  to	  hours	  depending	  on	  the	  intensity,	  polarity,	  and	  duration	  of	  stimulation	  (Nitsche	  &	  Paulus	  2000;	  Priori	  et	  al.,	  2003).	  	  Stimulation	  is	  typically	  administered	  using	  relatively	  large	  (25	  cm2	  or	  35cm2)	  pads	  that	  are	  moistened	  with	  saline	  to	  facilitate	  electrical	  conduction,	  although	  systems	  that	  use	  smaller	  electrodes	  for	  “high-­‐definition”	  stimulation	  are	  becoming	  more	  widely	  available	  (Datta	  et	  al.,	  2009).	  The	  area	  of	  brain	  stimulated	  during	  conventional	  tDCS	  is	  presumed	  to	  be	  more	  diffuse	  than	  that	  stimulated	  using	  TMS,	  which	  generally	  obviates	  the	  need	  for	  image-­‐guided	  neuronavigational	  systems.	  Given	  its	  ease	  of	  administration,	  versatility,	  and	  minimal	  side	  effects,	  there	  has	  recently	  been	  an	  upsurge	  of	  interest	  in	  the	  use	  of	  tDCS	  for	  both	  research	  and	  clinical	  purposes.	  Direct	  current	  stimulation	  is	  being	  explored	  as	  a	  therapy	  for	  many	  of	  the	  same	  conditions	  as	  TMS,	  including	  but	  not	  limited	  to	  stroke	  recovery,	  mood	  and	  anxiety	  disorders,	  chronic	  pain,	  and	  Parkinsonism.	  tDCS	  as	  not	  yet	  been	  approved	  by	  the	  FDA	  for	  any	  therapeutic	  indication,	  and	  treatments	  are	  therefore	  considered	  “off-­‐label”	  applications	  of	  this	  technology	  (see	  Utz	  et	  al.,	  2010	  for	  a	  review).	  In	  addition	  to	  tDCS,	  other	  electrical	  brain	  stimulation	  techniques	  are	  emerging	  as	  potentially	  promising	  approaches	  for	  modulating	  brain	  activity.	  These	  include	  transcranial	  alternating	  current	  stimulation	  (tACS),	  a	  technique	  wherein	  alternating	  current	  is	  applied	  through	  the	  scalp	  to	  the	  brain	  in	  a	  frequency-­‐specific	  manner	  (Kanai	  et	  al.,	  2008),	  and	  transcranial	  random	  noise	  stimulation	  (TRNS),	  which	  involves	  the	  application	  of	  a	  random	  electrical	  oscillation	  spectrum	  to	  the	  brain	  (Terney	  et	  al.,	  2008).	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EVIDENCE	  ON	  EFFECTIVENESS	  AND	  SAFETY	  
	  Recent	  discussions	  in	  the	  fields	  of	  experimental	  psychology	  and	  clinical	  trial	  research	  have	  focused	  on	  the	  importance	  of	  study	  power	  and	  replication	  (e.g.,	  Ioannidis,	  J.P.,	  2005.	  Simmons,	  Nelson	  &	  Simonsohn,	  2011).	  	  It	  is	  difficult	  to	  assess	  the	  effectiveness	  of	  current	  neurocognitive	  enhancement	  methods	  for	  reasons	  highlighted	  in	  these	  discussions:	  	  Most	  studies	  are	  small	  and	  under-­‐powered	  to	  find	  anything	  but	  large	  effects;	  many	  studies	  utilize	  multiple	  outcome	  measures,	  which	  further	  compromises	  power	  if	  correction	  for	  multiple	  comparisons	  is	  applied,	  or	  raises	  the	  risk	  of	  false	  positive	  results	  if	  no	  correction	  is	  applied,	  and	  of	  course	  none	  of	  the	  studies	  are	  registered	  in	  advance	  so	  there	  is	  no	  way	  to	  know	  how	  many	  null	  results	  have	  gone	  unreported.	  	  These	  challenges	  afflict	  virtually	  all	  research	  in	  the	  area	  of	  enhancement,	  including	  research	  carried	  out	  by	  highly	  competent	  and	  honest	  researchers.	  	  It	  seems	  likely	  to	  us	  that	  the	  methods	  of	  cognitive	  enhancement	  reviewed	  here	  have	  some	  benefit,	  for	  some	  users,	  relative	  to	  placebo,	  but	  how	  much	  benefit	  and	  for	  whom	  is	  difficult	  to	  know	  given	  the	  current	  state	  of	  the	  research.	  	  	  That	  research	  is	  summarized	  briefly	  here.	  	  
Effectiveness	  and	  safety	  of	  drugs.	  	  All	  three	  classes	  of	  medication	  have	  been	  reported	  to	  enhance	  performance	  in	  certain	  laboratory	  cognitive	  tasks	  for	  at	  least	  some	  normal	  healthy	  subjects.	  	  However,	  the	  true	  reliability	  and	  size	  of	  these	  effects,	  and	  their	  usefulness	  for	  real-­‐world	  cognitive	  enhancement,	  have	  not	  been	  definitively	  established.	  	  These	  matters	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are	  difficult	  to	  determine	  on	  the	  basis	  of	  the	  current	  literature.	  	  Indeed,	  there	  is	  reason	  to	  be	  skeptical	  concerning	  the	  cognitive	  enhancement	  potential	  of	  these	  medications.	  	  The	  largest	  literature	  on	  pharmacologic	  cognitive	  enhancement	  concerns	  the	  stimulants.	  Recent	  reviews	  and	  meta-­‐analyses	  have	  found	  mixed	  results	  and	  some	  have	  gone	  so	  far	  as	  to	  conclude	  that	  the	  drugs	  offer	  no	  benefit	  to	  normal	  individuals.	  	  For	  example,	  Chamberlain,	  Robbins,	  Winder-­‐Rhodes,	  Muller,	  Sahakian,	  Blackwell	  and	  Barnett	  (2010)	  reviewed	  studies	  in	  which	  CANTAB	  tasks	  had	  been	  used	  to	  assess	  stimulant	  effects	  in	  patients	  and	  healthy	  control	  participants.	  	  They	  concluded	  that	  “acute	  doses	  of	  medication	  improved	  aspects	  of	  cognition,	  though	  findings	  were	  more	  consistent	  in	  subjects	  with	  ADHD	  than	  in	  healthy	  volunteers.”	  In	  the	  words	  of	  Repantis,	  Schlattmann,	  Laisney	  and	  Heuser	  (2010)	  concerning	  methylphenidate	  as	  well	  as	  modafinil,	  “expectations	  regarding	  the	  effectiveness	  of	  these	  drugs	  exceed	  their	  actual	  effects.”	  	  Hall	  and	  Lucke	  (2010)	  state	  that	  “There	  is	  very	  weak	  evidence	  that	  putatively	  neuroenhancing	  pharmaceuticals	  in	  fact	  enhance	  cognitive	  function.”	  	  An	  even	  stronger	  conclusion	  was	  presented	  by	  Advokat	  (2010),	  whose	  reading	  of	  the	  literature	  led	  her	  to	  suggest	  that	  “studies	  in	  non-­‐ADHD	  adults	  suggest	  that	  stimulants	  may	  actually	  impair	  performance	  of	  tasks	  that	  require	  adaptation,	  flexibility	  and	  planning.”	  	  At	  least	  two	  studies	  have	  documented	  paradoxical	  impairment	  of	  cognitive	  performance	  by	  stimulants	  in	  certain	  subsets	  of	  people	  (Farah,	  Haimm,	  Sankoorikal,	  Smith	  &	  Chatterjee,	  2008;	  Mattay,	  Goldberg,	  Fera,	  Hariri,	  Tessitore,	  Egan	  &	  Weinberger,	  2003).	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We	  recently	  surveyed	  more	  than	  fifty	  experiments	  on	  the	  effects	  of	  amphetamine	  and	  methylphenidate	  on	  a	  wide	  array	  of	  cognitive	  functions,	  including	  memory	  (episodic	  and	  nonepisodic	  memory)	  and	  executive	  functions	  (working	  memory,	  cognitive	  control)	  in	  healthy	  young	  adults	  (Smith	  &	  Farah,	  2011).	  We	  discovered	  a	  roughly	  even	  mixture	  of	  significant	  enhancement	  effects	  and	  null	  findings.	  Studies	  examining	  stimulants’	  effects	  on	  episodic	  memory	  revealed	  an	  enhancing	  effect	  of	  stimulants	  on	  learning	  under	  some	  circumstances,	  specifically	  when	  the	  retention	  interval	  between	  study	  and	  test	  was	  longer	  than	  an	  hour,	  but	  not	  at	  shorter	  intervals.	  	  The	  evidence	  on	  enhancement	  of	  executive	  functions	  was	  much	  less	  clear.	  	  Although	  there	  were	  many	  studies	  reporting	  significant	  enhancing	  effects	  of	  stimulants	  in	  working	  memory,	  there	  were	  also	  many	  null	  results.	  In	  addition,	  when	  significant	  effects	  were	  found,	  they	  were	  sometimes	  qualified	  by	  complex	  interactions	  between	  the	  order	  in	  which	  participants	  performed	  tasks,	  participants’	  level	  of	  ability	  on	  placebo,	  and	  participants’	  genotypes.	  The	  same	  was	  true	  of	  stimulant	  effects	  on	  cognitive	  control.	  	  In	  a	  more	  recently	  completed	  study	  (Ilieva,	  Boland	  &	  Farah,	  2013)	  examining	  the	  effects	  of	  amphetamine	  on	  13	  different	  measures	  of	  cognitive	  performance	  using	  a	  design	  with	  sufficient	  power	  to	  detect	  a	  medium-­‐size	  effect	  in	  any	  one	  measure,	  we	  failed	  to	  find	  any	  evidence	  of	  reliable	  enhancement.	  	  Participants	  in	  this	  study	  did,	  however,	  tend	  to	  believe	  their	  performance	  was	  enhanced	  when	  on	  the	  drug	  relative	  to	  the	  placebo.	  	  Our	  finding	  that	  participants	  tended	  to	  judge	  the	  amphetamine	  more	  enhancing	  than	  the	  placebo	  raises	  the	  possibility	  that	  it	  may	  be	  the	  noncognitive	  effects	  of	  stimulants	  that	  are	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most	  enhancing	  of	  work	  performance.	  	  The	  effects	  of	  stimulants	  on	  subjective	  energy,	  confidence	  and	  motivation	  have	  been	  noted	  by	  students	  as	  being	  among	  the	  helpful	  effects	  of	  amphetamine	  (cf.	  DeSantis	  et	  al.,	  2008;	  Ilieva	  &	  Farah,	  under	  review;	  Vrecko,	  2013).	  	  Military	  psychologists	  in	  the	  mid-­‐20th	  century	  reached	  similar	  conclusions	  about	  the	  usefulness	  of	  stimulants	  for	  enhancing	  the	  performance	  of	  personnel	  (see,	  eg,	  Hurst,	  1966).	  	  The	  much	  smaller	  literature	  on	  the	  effects	  of	  acetylcholinesterase	  inhibitors	  on	  normal	  cognition	  was	  reviewed	  by	  Repantis,	  Laisney	  and	  Heuser	  (2010).	  	  The	  majority	  of	  the	  studies	  used	  donepezil	  (Aricept)	  with	  healthy	  young	  or	  elderly	  adults,	  in	  either	  single-­‐dose	  or	  chronic	  administrations,	  and	  assessed	  various	  aspects	  of	  learning	  and	  memory.	  	  Summarizing	  the	  mix	  of	  null	  results,	  positive	  results	  and	  two	  instances	  of	  drug-­‐induced	  impairment,	  the	  authors	  describe	  the	  literature	  as	  “provid[ing]	  no	  consistent	  evidence	  for	  a	  neuroenhancement	  effect”	  (p.	  480).	  	  Finally,	  the	  effects	  of	  single	  doses	  of	  modafinil	  on	  cognitive	  ability	  has	  been	  studied	  with	  both	  sleep-­‐deprived	  and	  normally	  rested	  healthy	  adults.	  	  As	  mentioned	  earlier,	  here	  is	  clear	  evidence	  of	  improved	  executive	  function	  and	  memory	  for	  sleep-­‐deprived	  individuals	  (e.g.,	  Wesenten,	  2006).	  	  In	  contrast,	  with	  rested	  adults	  we	  find	  the	  familiar	  pattern	  of	  positive	  findings	  in	  certain	  tasks,	  for	  example	  inhibitory	  control	  (Turner	  et	  al.,	  2003),	  but	  a	  large	  number	  of	  null	  results	  and	  the	  occasional	  finding	  of	  impairment	  (see,	  e.g.,	  Chamberlain	  et	  al.,	  2010,	  Kelley	  et	  al.,	  2012	  and	  Repantis	  et	  al.,	  2010	  for	  reviews).	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The	  safety	  of	  pharmacologic	  cognitive	  enhancement	  varies	  according	  to	  the	  drug	  used	  as	  well	  as	  the	  dosage	  and	  frequency	  of	  usage.	  	  All	  drugs	  are	  widely	  used	  therapeutically;	  their	  safety	  profiles	  in	  the	  therapeutic	  context	  are	  well	  documented	  and	  will	  not	  be	  explored	  in	  detail	  here.	  	  However,	  one	  type	  of	  risk	  should	  be	  singled	  out	  for	  comment	  and	  that	  is	  the	  risk	  of	  dependence	  (Volkow	  &	  Swanson,	  2008).	  	  Stimulants	  are	  potentially	  habit-­‐forming,	  and	  nationwide	  survey	  analyzed	  by	  Kroutil	  and	  colleagues	  (2006)	  estimated	  that	  almost	  one	  in	  20	  nonmedical	  users	  of	  prescription	  stimulants	  meets	  criteria	  for	  dependence	  or	  abuse.	  The	  risk	  to	  individuals	  using	  these	  medications	  specifically	  for	  cognitive	  enhancement	  is	  not	  known.	  	  
Effectiveness	  and	  safety	  of	  brain	  stimulation.	  	  TMS	  and	  tDCS	  have	  become	  important	  research	  tools	  for	  understanding	  the	  neural	  substrates	  of	  cognition	  in	  the	  human	  brain	  and	  have	  shown	  promise	  for	  a	  variety	  of	  therapeutic	  applications.	  	  Research	  directed	  toward	  these	  goals	  often	  involves	  administering	  brain	  stimulation	  to	  healthy	  normal	  humans	  and	  measuring	  the	  effects	  on	  cognition.	  	  Hence	  many	  studies	  provide	  an	  indication	  of	  the	  potential	  of	  noninvasive	  brain	  stimulation	  for	  cognitive	  enhancement.	  	  Both	  TMS	  and	  tDCS	  have	  been	  used	  with	  healthy	  volunteers	  to	  induce	  transient	  or	  more	  lasting	  improvement	  in	  a	  variety	  of	  cognitive	  domains.	  	  Hamilton,	  Messing	  and	  Chatterjee	  (2011)	  have	  reviewed	  the	  empirical	  literature	  on	  cognitive	  enhancement	  with	  noninvasive	  brain	  stimulation	  and,	  along	  with	  Cohen	  Kadosh,	  Levy,	  	  O’Shea,	  Shea	  and	  Savulescu	  (2012),	  have	  discussed	  the	  ethical	  implications	  of	  this	  practice.	  	  There	  are	  numerous	  reports	  of	  enhanced	  learning,	  working	  memory	  and	  other	  executive	  functions	  following	  TMS	  or	  tDCS	  stimulation,	  particularly	  when	  activating	  left	  frontal	  regions.	  	  Enduring	  enhancement	  of	  simple	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mathematical	  thinking	  processes	  have	  been	  achieved	  by	  tDCS	  and	  tRNS	  of	  parietal	  cortex	  (Cohen	  Kadosh	  et	  al.,	  2010;	  Snowball	  et	  al.,	  2013).	  	  There	  are	  also	  reports	  that	  creative	  problem	  solving	  can	  be	  enhanced	  with	  noninvasive	  brain	  stimulation,	  in	  one	  case	  quite	  spectacularly	  (Chi	  &	  Snyder,	  2012).	  	  Despite	  the	  great	  promise	  shown	  by	  noninvasive	  brain	  stimulation	  methods	  so	  far,	  we	  hesitate	  to	  draw	  firm	  conclusions	  about	  the	  potential	  of	  these	  techniques	  for	  cognitive	  enhancement.	  	  The	  research	  literature	  on	  stimulant	  medications	  seemed	  initially	  to	  support	  their	  potential	  as	  cognitive	  enhancers.	  	  The	  current	  state	  of	  the	  brain	  stimulation	  literature	  gives	  reason	  for	  optimism	  but	  does	  not	  definitively	  settle	  the	  issue	  of	  whether	  these	  techniques	  will	  be	  helpful	  for	  normal	  healthy	  individuals	  seeking	  to	  improve	  their	  cognitive	  abilities.	  	  In	  the	  coming	  years,	  replications	  and	  extensions	  of	  earlier	  findings	  will	  deliver	  the	  evidence	  that	  we	  currently	  lack	  (see	  Koenigs	  et	  al.,	  2009).	  	  The	  most	  significant	  safety	  risk	  associated	  with	  TMS	  is	  the	  possibility	  of	  causing	  a	  seizure.	  However,	  when	  administered	  within	  the	  established	  safety	  guidelines,	  the	  risk	  of	  seizure	  induction	  is	  extremely	  low	  (Rossi	  et	  al.,	  2009).	  	  The	  safety	  profile	  of	  tDCS	  is	  even	  better	  than	  that	  of	  TMS.	  	  Side	  effects	  of	  acute	  tDCS	  include	  sensations	  such	  as	  tingling,	  burning	  or	  pain,	  rarely	  experienced	  as	  severe	  (Kessler	  et	  al.,	  2012)	  and	  no	  serious	  adverse	  health	  events	  have	  ever	  been	  reported	  using	  this	  technology.	  	  
General	  conclusions	  regarding	  effectiveness	  of	  current	  cognitive	  enhancement	  
methods.	  	  Given	  the	  small	  size	  of	  most	  of	  the	  relevant	  studies	  (typically	  samples	  of	  just	  a	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few	  dozen	  subjects	  or	  fewer,	  limiting	  the	  sensitivity	  of	  the	  research),	  and	  the	  likelihood	  of	  publication	  bias	  against	  null	  results,	  it	  is	  difficult	  to	  draw	  definite	  conclusions	  concerning	  the	  cognitive	  enhancing	  effects	  of	  either	  the	  drugs	  or	  stimulation	  methods	  discussed	  here.	  	  	  While	  the	  number	  of	  positive	  results	  makes	  it	  seem	  likely	  that	  cognition	  can	  indeed	  be	  enhanced	  in	  the	  laboratory	  with	  drugs	  and	  with	  noninvasive	  brain	  stimulation	  –	  an	  implausibly	  large	  number	  of	  unpublished	  null	  or	  reverse	  effects	  would	  have	  to	  exist	  to	  attribute	  all	  enhancement	  effects	  to	  publication	  bias	  –	  it	  is	  difficult	  to	  know	  the	  true	  size	  and	  generality	  of	  these	  effects	  at	  present.	  	  In	  addition,	  no	  studies	  have	  yet	  assessed	  the	  carryover	  from	  effects	  on	  laboratory	  tests	  of	  cognition	  to	  effects	  real-­‐world	  academic	  and	  occupational	  performance	  with	  normal	  healthy	  subjects.	  	  On	  the	  one	  hand,	  small	  effects	  might	  only	  show	  themselves	  in	  the	  carefully	  controlled	  context	  of	  laboratory	  study.	  	  Such	  effects	  might	  become	  imperceptible	  in	  real-­‐world	  work	  situations.	  	  On	  the	  other	  hand,	  an	  effect	  that	  is	  small	  when	  measured	  in	  a	  single	  experimental	  session	  in	  the	  lab	  may	  compound	  itself	  in	  ongoing	  work	  situations	  and	  ultimately	  yield	  substantial	  benefits	  for	  the	  enhancement	  user.	  	  Without	  the	  necessary	  empirical	  research	  it	  is	  impossible	  to	  know	  how	  the	  cognitive	  enhancers	  reviewed	  here	  might	  impact	  real-­‐world	  users.	  	  
EVIDENCE	  ON	  PREVALENCE	  	  It	  is	  not	  easy	  to	  estimate	  the	  prevalence	  of	  cognitive	  enhancement.	  	  People	  are	  generally	  reluctant	  to	  admit	  using	  prescription	  medications	  for	  nonmedical	  reasons,	  and	  this	  is	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especially	  true	  of	  prescription	  stimulants,	  which	  are	  FDA	  Schedule	  II	  controlled	  substances.	  	  Surveys	  of	  prescription	  stimulant	  use	  have	  not,	  so	  far,	  been	  able	  to	  deliver	  accurate	  estimates	  of	  pharmaceutical	  cognitive	  enhancement	  in	  the	  population	  at	  large,	  and	  to	  our	  knowledge	  no	  one	  has	  attempted	  a	  systematic	  survey	  in	  connection	  with	  brain	  stimulation.	  	  Whether	  involving	  drugs	  or	  devices,	  the	  prevalence	  of	  cognitive	  enhancement	  will	  undoubtedly	  differ	  sharply	  according	  to	  age,	  gender,	  occupation,	  geographic	  region	  and	  other	  demographic	  variables,	  complicating	  the	  task	  of	  assessing	  prevalence.	  	  Notwithstanding	  these	  limitations,	  it	  is	  possible	  to	  draw	  some	  inferences	  from	  the	  available	  evidence,	  if	  only	  for	  specific	  segments	  of	  the	  population.	  	  Two	  journals,	  Nature	  and	  Wired,	  queried	  readers	  about	  their	  use	  of	  pharmaceutical	  cognitive	  enhancement.	  	  Although	  the	  survey	  samples	  were	  idiosyncratic	  –	  people	  who	  read	  the	  journals	  and	  had	  sufficient	  interest	  in	  the	  topic	  of	  cognitive	  enhancement	  to	  respond	  –	  the	  results	  can	  be	  viewed	  as	  a	  kind	  of	  existence	  proof	  that	  cognitive	  enhancement	  is	  being	  attempted	  by	  some.	  Nature’s	  survey	  was	  reported	  in	  statistical	  terms,	  including	  a	  20%	  rate	  of	  self-­‐reported	  cognitive	  enhancement	  among	  respondents	  (Maher,	  2008).	  	  Wired	  then	  asked	  readers	  to	  write	  in	  to	  share	  their	  cognitive	  enhancing	  regimens,	  and	  received	  50	  reports	  of	  “scientists,	  college	  students	  and	  business	  owners”	  using	  all	  of	  the	  drugs	  discussed	  earlier	  (Madrigal,	  2008).	  	  	  	  Academic	  researchers	  have	  examined	  the	  prevalence	  of	  cognitive	  enhancement	  with	  prescription	  stimulants	  among	  students	  and	  found	  widely	  varying	  rates	  of	  use.	  	  Research	  with	  various	  campus	  samples	  of	  convenience	  in	  the	  US	  have	  yielded	  rates	  of	  between	  2.5%	  to	  55%	  (see	  Smith	  &	  Farah,	  2011,	  for	  a	  review),	  depending	  on	  the	  nature	  of	  the	  sample	  and	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specific	  wording	  of	  the	  question	  (e.g.,	  lifetime	  use	  versus	  past	  month	  use).	  	  The	  largest	  and	  best-­‐designed	  survey	  of	  prescription	  stimulant	  use	  by	  American	  undergraduates	  was	  undertaken	  with	  a	  representative	  sample	  of	  10,904	  students	  from	  119	  different	  colleges	  and	  universities	  in	  2001	  (McCabe,	  Knight,	  Teter	  &	  Wechsler,	  2005).	  	  It	  estimated	  that,	  among	  American	  college	  students,	  6.9%	  had	  used	  prescription	  stimulants	  nonmedically	  in	  their	  lifetime	  and	  4.1%	  had	  done	  so	  in	  the	  past	  year.	  	  It	  also	  found	  large	  differences	  between	  the	  prevalence	  of	  this	  practice	  in	  different	  parts	  of	  the	  US,	  at	  different	  categories	  of	  schools,	  and	  among	  different	  types	  of	  students.	  	  The	  highest	  rates	  were	  found	  at	  competitive,	  Northeastern	  institutions,	  among	  sorority/fraternity	  members,	  more	  likely	  male	  and	  with	  grade	  point	  averages	  of	  B	  or	  lower.	  	  Unfortunately,	  like	  the	  larger	  national	  surveys	  of	  illicit	  drug	  use	  in	  the	  US	  (the	  National	  Survey	  on	  Drug	  Use	  and	  Health	  and	  Monitoring	  the	  Future),	  this	  survey	  did	  not	  distinguish	  between	  nonmedical	  use	  as	  a	  study	  aid	  and	  as	  a	  recreational	  drug.	  	  	  	  This	  group	  did	  carry	  out	  a	  large	  survey	  of	  undergraduates	  at	  a	  single	  university	  and	  found	  that	  the	  most	  commonly	  mentioned	  reasons	  for	  nonmedical	  stimulant	  use	  were	  to	  enhance	  concentration	  and	  alertness,	  but	  that	  a	  substantial	  number	  of	  students	  also	  sought	  the	  drugs’	  “high”	  (Teter	  et	  al.,	  2005),	  a	  finding	  consistent	  with	  many	  smaller	  studies	  at	  diverse	  institutions	  (see	  Smith	  &	  Farah,	  2011,	  for	  a	  review).	  	  Little	  is	  known	  about	  global	  patterns	  of	  cognitive	  enhancement.	  	  It	  seems	  that	  North	  American	  students	  are	  more	  likely	  to	  use	  prescription	  stimulants	  for	  enhancement	  than	  students	  from	  several	  other	  countries	  surveyed,	  although	  the	  small	  convenience	  samples	  used	  in	  most	  of	  these	  studies	  precludes	  firm	  conclusions	  (Franke	  et	  al.,	  2011;	  Partridge	  et	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al.,	  2013;	  Ragan	  et	  al.,	  2013).	  	  	  	  To	  our	  knowledge	  there	  is	  no	  systematic	  research	  on	  the	  use	  of	  noninvasive	  brain	  stimulation	  for	  nonmedical	  reasons	  including	  cognitive	  enhancement.	  However,	  media	  coverage	  suggests	  that	  the	  idea	  has	  captured	  the	  attention	  and	  imagination	  of	  the	  public	  (e.g.	  Adee,	  2012;	  Oremus,	  2013).	  The	  notion	  that	  a	  “thinking	  cap”	  can	  improve	  normal	  performance	  has	  been	  spurred	  by	  the	  advent	  of	  tDCS	  as	  a	  therapeutic	  and	  investigational	  tool.	  	  Although	  TMS	  has	  been	  used	  in	  research	  and	  clinical	  settings	  for	  over	  25	  years,	  the	  practical	  limitations	  of	  magnetic	  brain	  stimulation	  have	  largely	  curtailed	  interest	  in	  its	  use	  in	  normal	  individuals.	  	  TMS	  units	  are	  cumbersome	  and	  expensive,	  require	  technical	  expertise	  to	  operate,	  are	  associated	  with	  at	  least	  some	  medical	  risk,	  and	  are	  generally	  only	  available	  in	  laboratories	  or	  clinical	  settings.	  By	  contrast,	  tDCS	  is	  inexpensive,	  portable,	  easy	  to	  administer,	  and	  apparently	  safe—properties	  that	  are	  conducive	  to	  popular	  usage.	  Moreover,	  the	  construction	  of	  a	  basic	  tDCS	  device	  is	  relatively	  straightforward	  from	  an	  engineering	  standpoint	  and	  can	  be	  done	  inexpensively	  using	  readily	  available	  materials.	  This	  has	  led	  a	  few	  aspiring	  entrepreneurs	  and	  “do-­‐it-­‐yourself”	  enthusiasts	  to	  construct	  tDCS	  units	  that	  are	  available	  for	  purchase	  by	  the	  public	  (e.g.,	  http://flowstateengaged.com,	  http://www.foc.us/).	  Although	  it	  is	  not	  possible	  to	  quantify	  the	  number	  of	  people	  employing	  tDCS	  or	  other	  forms	  of	  noninvasive	  brain	  stimulation	  outside	  of	  research	  and	  medicine,	  an	  examination	  of	  publically	  accessible	  websites,	  blogs,	  and	  other	  social	  media	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has	  turned	  up	  a	  number	  of	  intrepid	  individuals	  already	  engaged	  in	  self-­‐stimulation	  for	  the	  purposes	  of	  cognitive	  enhancement.	  	  
CONCLUSIONS:	  ISSUES	  IN	  NEED	  OF	  FURTHER	  RESEARCH	  	  There	  are	  surprisingly	  few	  generalizations	  about	  cognitive	  enhancement	  that	  can	  be	  stated	  with	  confidence	  at	  present.	  	  Published	  research	  demonstrates	  that	  medications	  and	  noninvasive	  brain	  stimulation	  can	  enhance	  certain	  cognitive	  abilities	  in	  normal	  healthy	  individuals,	  although	  the	  robustness	  of	  these	  effects	  –	  their	  true	  size,	  replicability,	  and	  generalizability	  to	  nonlaboratory	  conditions	  –	  is	  unknown.	  	  Also	  poorly	  understood	  at	  present	  are	  the	  possible	  negative	  consequences	  of	  these	  practices,	  from	  paradoxical	  impairment	  of	  performance	  in	  some	  to	  the	  potential	  for	  dependency	  and	  addiction.	  	  At	  the	  same	  time,	  we	  know	  that	  some	  people	  are	  sufficiently	  convinced	  of	  the	  benefits	  of	  cognitive	  enhancement	  that	  they	  have	  become	  regular	  users.	  We	  have	  a	  sense	  of	  the	  scope	  of	  prescription	  stimulant	  use	  for	  cognitive	  enhancement	  in	  academia,	  but	  little	  beyond	  anecdotes	  and	  existence	  proofs	  where	  other	  populations	  and	  practices	  are	  concerned.	  	  Given	  the	  public	  health	  implications	  of	  potentially	  large	  numbers	  of	  healthy	  people	  using	  drugs	  and	  devices	  without	  medical	  supervision,	  we	  believe	  that	  a	  better	  understanding	  of	  the	  effects,	  side	  effects	  and	  prevalence	  of	  these	  methods	  is	  a	  research	  priority.	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